Evidence map›Paper›PMID 40420168›Full record

ArticleExperimental hematology & oncology2025

Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRAS

Jeffrey Xiao, Joshua Kim, Brandon Park, David J Baylink, Cedric Kwon, Victoria Tran, Scott Lee, Kevin Codorniz, Laren Tan, Pamela Lobo Moreno and 12 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jeffrey Xiao *Division of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Joshua Kim *Division of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Brandon Park *Division of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
David J BaylinkDivision of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Cedric KwonDivision of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Victoria TranDivision of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Scott LeeDivision of Endocrinology, Diabetes & Metabolism, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Kevin CodornizDivision of Endocrinology, Diabetes & Metabolism, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Laren TanDivision of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Pamela Lobo MorenoDivision of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Amy Schill-DepewDivision of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Saied MirshahidiBiospecimen Laboratory, Department of Medicine and Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
David De SemirCaris Life Sciences, Inc, Phoenix, 85040, AZ, USA.
Diana HannaNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, CA, USA.
Kiran NaqviDivision of Hematology and Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, 92868, USA.
Huynh CaoDivision of Hematology and Oncology, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Chien-Shing ChenDivision of Hematology and Oncology, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Joanne XiuCaris Life Sciences, Inc, Phoenix, 85040, AZ, USA.
Heinz-Josef LenzNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, CA, USA.
Hamid MirshahidiDivision of Hematology and Oncology, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Mark E ReevesDivision of Hematology and Oncology, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA.
Yi XuDivision of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda, 92354, CA, USA. dyxu@llu.edu.

Funding

Loma Linda University GRASPLoma Linda University Research Innovation Grant
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a 5-year overall survival (OS) rate of approximately 12%. More than 90% of PDAC patients harbor oncogenic mutations in the Kirsten rat sarcoma viral homolog (KRAS) gene. MRTX1133 (MRTX), a novel inhibitor of KRAS

Indexed as

ATPBedaquilineDDITHelicaseKRASMitochondrionMRTX1133NFκB2PDACS100P

Identifiers

PMID40420168
PMCPMC12105384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.